Non-small cell lung cancer
Not recruitingStudy on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer
Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancer
- Substances:OsimertinibDatopotamab Deruxtecan
Germany- Participants:18–64 years · 65+ years
- Substances:Osimertinib
- Sponsor:AstraZeneca AB












